Abstract
While subarachnoid hemorrhage is the second most common hemorrhagic stroke in epidemiologic studies, the recent DISCHARGE-1 trial has shown that in reality, three-quarters of focal brain damage after subarachnoid hemorrhage is ischemic. Two-fifths of these ischemic infarctions occur early and three-fifths are delayed. The vast majority are cortical infarcts whose pathomorphology corresponds to anemic infarcts. Therefore, we propose in this review that subarachnoid hemorrhage as an ischemic-hemorrhagic stroke is rather a third, separate entity in addition to purely ischemic or hemorrhagic strokes. Cumulative focal brain damage, determined by neuroimaging after the first 2 weeks, is the strongest known predictor of patient outcome half a year after the initial hemorrhage. Because of the unique ability to implant neuromonitoring probes at the brain surface before stroke onset and to perform longitudinal MRI scans before and after stroke, delayed cerebral ischemia is currently the stroke variant in humans whose pathophysiological details are by far the best characterized. Optoelectrodes located directly over newly developing delayed infarcts have shown that, as mechanistic correlates of infarct development, spreading depolarizations trigger (1) spreading ischemia, (2) severe hypoxia, (3) persistent activity depression, and (4) transition from clustered spreading depolarizations to a negative ultraslow potential. Furthermore, traumatic brain injury and subarachnoid hemorrhage are the second and third most common etiologies of brain death during continued systemic circulation. Here, we use examples to illustrate that although the pathophysiological cascades associated with brain death are global, they closely resemble the local cascades associated with the development of delayed cerebral infarcts.
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Introduction
Subarachnoid hemorrhage (SAH) is a life-threatening cerebrovascular event. In about 85% of cases, it is caused by the rupture of a cerebral aneurysm. Damage of brain tissue in the context of aneurysmal SAH (aSAH) is due to (1) the initial global cerebral ischemia which at least in part might be due to increase in intracranial pressure (ICP), (2) the accumulation of blood in the subarachnoid space, (3) the intraventricular blood accumulation, (4) the direct destruction of brain tissue by intracerebral hemorrhage (ICH), and (5) the occurrence of focal cerebral ischemia. Focal ischemic damage develops both in the early phase (early cerebral ischemia (ECI)) (initial ~ 48 h) [1,2,3] and in the delayed phase (delayed cerebral ischemia (DCI)) [4,5,6] (48 h until ~ 2 weeks).
The prospective, observational, multicenter, diagnostic phase III trial DISCHARGE-1 recently found that cumulative focal brain damage from ICH, ECI, and DCI up to Day 14, as determined by neuroimaging, is the strongest known predictor of patient outcome half a year after the initial hemorrhage [7]. In DISCHARGE-1, on average 61.2 ± 100.3 ml (76.0%) of the total focal brain damage per patient was ischemic (ECI and DCI) and 19.4 ± 29.1 ml (24.0%) was hemorrhagic (ICH) (p < 0.001, n = 180, Mann–Whitney Rank Sum Test). In other words, about three-quarters of the focal brain damage after aSAH was ischemic. The average damage caused by ECI amounted to 26.9 ± 66.9 ml. The 170 survivors of the early phase developed an average volume of 36.3 ± 80.1 ml of damaged tissue due to DCI. The vast majority of these infarcts are located in the cerebral cortex and pathomorphologically they are almost without exception so-called anemic infarcts [3, 8,9,10,11,12,13,14].
Since severe aSAH is composed of different subtypes of stroke, in contrast to a spontaneous ICH [15], we believe it would be more accurate to refer to aSAH as an ischemic-hemorrhagic stroke rather than a simple hemorrhagic stroke. Thus, especially for research into the pathophysiological basis of the development of brain damage associated with cerebral ischemia in humans, the study of aSAH during neurocritical care is of great fundamental importance far beyond aSAH. For the following reasons, aSAH is even recognized as a model disease for cerebral ischemia in humans [16]: DCI usually occurs while the patient is already in the neurocritical care unit. Clinical studies on thrombolytic and endovascular treatment of ischemic stroke have shown that rescue therapies are most effective when administered early after the onset of ischemia [17, 18] summarized in the motto “time is brain” [19]. Patients with DCI could theoretically even be treated before the tissue damage begins. However, besides the fact that there is currently no effective, evidence-based therapy for DCI [20], another relevant difficulty is to recognize the onset of DCI in time, as typical patients with severe aSAH and high risk of DCI are often comatose. The latter is also the reason why it is so difficult to test novel approaches to the treatment of DCI in a meaningful way. However, to possibly overcome this difficulty, it is interesting that neurosurgical interventions are indicated in patients early after the initial hemorrhage so that invasive probes can be implanted. This provides a unique opportunity to invasively monitor the entire period of ischemic stroke development, perform early treatment stratification based on changes in diagnostic summary measures captured in real time via invasive neuromonitoring techniques, and then capture the responses of the diagnostic summary measures to the intervention to save the tissue. This corresponds to the concept of so-called precision (individualized) medicine [21]. Due to the recent refinement of minimally invasive procedures [22,23,24], this approach is currently becoming increasingly available also for patients who do not require craniotomy during neurocritical care.
In the last decade, major interim scientific successes on this road to precision medicine of DCI were human recordings, in patients with aSAH, that characterized the electrocorticographic (ECoG) hallmarks of (1) brain infarct development [25], (2) brain death development during continued systemic circulation [26, 27], and (3) brain death in the wake of cardiocirculatory arrest [28]. In addition, the dying process in the wake of cardiocirculatory arrest was also recorded in TBI patients and in one patient with malignant hemispheric stroke [28].
Severe TBI has become the other model disease for progressive brain damage during neurocritical care, as neurosurgical interventions allowing implantation of invasive probes are also often indicated after this condition [29,30,31,32]. In addition, bleeding into the subarachnoid space can also occur as a result of TBI, meaning that TBI patients are also at risk of DCI [33, 34]. Accordingly, there are important pathophysiological overlaps in the mechanisms between TBI and aSAH [22, 35], although DCI is overall more frequent and severe in aSAH patients [7] than in TBI patients [36, 37]. The further refinement of minimally invasive procedures [22,23,24] is also applicable to TBI, increasing the number of neurotrauma patients who might benefit from invasive neuromonitoring during neurocritical care.
Building on these introductory considerations, in the first part of this review, we will look at the epidemiological significance of aSAH as an ischemic-hemorrhagic stroke in comparison to purely ischemic and purely hemorrhagic (spontaneous ICH [15]) strokes. We will then briefly discuss the early phase and the delayed phase after aSAH and explain what spreading depolarizations (SD) are. On this basis, we will examine typical ECoG patterns of newly developing delayed cerebral infarcts, as intensivists will be increasingly confronted with such patterns due to the growing use of modern neuromonitoring techniques during the neurocritical care of aSAH and TBI patients. Finally, we will discuss typical ECoG patterns of brain death development during continued systemic circulation, as they occur globally but are otherwise very similar to patterns of local cerebral infarct development. In comatose patients in particular, we believe that understanding the nature and patterns of these harmful events and diagnosing them early, before it is too late to intervene, can make an important contribution to the development of therapeutic strategies to combat them. This is in line with the tenet espoused by Max Planck for science in general that “insight must precede application.”
Epidemiological Relevance of aSAH
The estimated global lifetime risk of ischemic stroke from the age of 25 years onward is 18.3%, and the risk of hemorrhagic stroke is 8.2% [38]. Spontaneous ICH is the most common form of hemorrhagic stroke. Its incidence is estimated at 25 per 100,000 person-years [39]. Spontaneous ICH accounts for 10–20% of all strokes [40, 41]. The estimated median case fatality of ICH at 1 month is ~ 40% (range 13–61) [39]. In epidemiologic studies, SAH is usually considered the second most common form of hemorrhagic stroke, which, as explained above, is not consistent with our pathophysiologic view, in which SAH as an ischemic-hemorrhagic stroke is rather a third, separate entity. The incidence of SAH is estimated at 8 per 100,000 person-years [42, 43] and accounts for only 5% of all strokes [44]. Case fatality of SAH varies between 27 and 44% for individual regions [45, 46].
Although the overall incidence of SAH is lower than that of pure ischemic stroke or ICH, the relatively young average age of SAH patients means that SAH accounts for almost the same proportion of potential years of life lost to stroke before the age of 65 (YPLL, a measure of premature mortality). In a US study, for example, it was estimated that 38.5% of stroke-related YPLL were due to ischemic stroke, 34.2% to ICH, and 27.3% to SAH (cf. Table 2 in Johnston et al. [47]). The estimated mean age of occurrence is 55 years for SAH [20], 65 years for ICH [48], and 70 years for ischemic stroke [49]. The estimated median age of death from SAH is 59 years compared with 73 years for ICH and 81 years for ischemic stroke [47]. The incidence of SAH in women is globally estimated to be 1.2 (95% confidence interval (95% CI), 1.1–1.4) times higher than in men [44]. In DISCHARGE-1, the median age was 55 years (interquartile range (IQR), 47–63) and the female-to-male ratio was 2.1:1 [7], which corresponds well with the nationwide female-to-male ratio in Germany of 1.8:1 [43]. The sex ratio is reverse for spontaneous ICH [48]. Thus, for example, in US women of European genetic background, an estimated 35.8% of stroke-related YPLL are due to SAH, while ischemic strokes and ICH account for only 34.7% and 29.5%, respectively [47].
Based on 1794 patients from four randomized clinical trials of tirilazad, sex was no predictor of poor patient outcome after aSAH [50]. However, not only are women more frequently affected by aSAH, but the negative socio-economic effects of aSAH also appear to be more serious for women than for men in a direct comparison. For example, in a study from Sweden, having sickness absence and/or disability pension at the end of the 3-year follow-up was predicted by a model consisting of (1) female sex, (2) living in a village/rural area, and (3) having a defined bleeding source for the SAH [51]. The female dominance in SAH has yet another unfavorable side effect, because in almost three-quarters of cases where a disease predominantly affects one sex, science funding is biased towards men, i.e., either the disease affects more women and is underfunded (in terms of burden) or the disease affects more men and is overfunded [52].
Although this is poorly captured in epidemiological studies [53], case fatality rates are likely to vary widely around the world since treatments for aSAH, which have led to better outcomes in countries with higher income [45], are among the most expensive in the entire healthcare system. This is because patients with aSAH are usually treated in critical care units according to the severity of the disease. In typical high-income countries such as Germany, for example, critical care accounts for around 20% of hospital costs with a share of only around 5% of hospital beds [54]. In addition, SAH is one of the four conditions that are most strongly associated with high costs among all critical care conditions [55]. The other three major independent cost drivers in critical care are (1) younger age, (2) acute respiratory failure requiring ventilation, and (3) complications related to procedures. There are only a few estimates of the total economic burden of SAH. For example, in 2005, this burden was estimated at £510 million annually in the UK alone [56]. This figure is related solely to SAH due to the rupture of a cerebral aneurysm.
The overall value of neurocritical care and emergency medicine is supported by a decrease in aSAH case-fatality rates by 17% between 1973 and 2002 [45]. In addition, the proportion of patients who regained independent function increased [53]. However, the curve of outcome improvement has leveled off over time and has recently stagnated. In particular, the prevalence of DCI did not decrease over time, as recently estimated by means of a random-effects meta-analysis of randomized controlled trials [57]. This stagnation is reflected in the fact that SAH patients remain the third most common group to experience brain death prior to circulatory collapse during critical care, following ICH and TBI in the top ranks. SAH is therefore also the third most prevalent disease as a source for organ transplantation [58].
Early and Delayed Phase After aSAH
In their review, Macdonald and Schweizer defined the delayed phase of brain injury by DCI as the period 3–14 days after the initial hemorrhage [20]. The Co-Operative Studies on Brain Injury Depolarizations (COSBID) group (www.cosbid.org) uses a naming convention, following the practice in most countries, of counting the first 24-h period after the initial insult as “Day 0,” the next 24-h period as “Day 1,” and so on [59]. Accordingly, “Day 2” in the COSBID studies including the recent DISCHARGE-1 trial on aSAH corresponds to the third day in the review by Macdonald and Schweizer, and the DCI phase would generally begin 48 h after the initial injury.
Based on the neuromonitoring data, however, there is overall a rather continuous transition from the early to the delayed phase with a statistical decrease in the initial damage processes up to Day 3 followed by a renewed increase from Day 4 (see supplementary Fig. 3 in Dreier et al. [7]). Accordingly, demarcated ischemic events in neuromonitoring can occur not only in the delayed phase, but also on any early day after the initial hemorrhage [25]. As a rule, this is hardly noticeable clinically, as most patients at risk of these events in the early period are deeply comatose. The classification into an early and a delayed phase after aSAH is statistically justified and helps clinicians and clinician scientists to simplify orientation. Nevertheless, it is important not to interpret this rigidly, but to bear in mind that biologically there is rather no precisely definable temporal boundary between the two phases.
As an example of the development of focal brain damage after aSAH, Fig. 1 shows an ICH and damage from ECI on postoperative MRI on Day 2 and the development of a large delayed ischemic infarct between the early MRI scan on Day 2 and two CT scans on Days 7 and 9 in a typical female patient in her forties. In order to ease understanding of the electrographic basis of the delayed infarct development in this patient, which is explained in Figs. 2 and 3, we would like to provide some general background information on SDs in the following.
The Role of SD in the Pathogenesis of Acute Brain Injury
Although SD is also presumably the mechanism of the comparatively harmless migraine aura [60,61,62,63], SD is primarily and with few exceptions [64] the key mechanism to understand how ischemic damage in gray matter of the nervous system occurs in virtually all species with a circulatory system [16, 65,66,67]. It is relatively irrelevant in this regard whether the ischemia occurs globally, e.g., in the context of circulatory arrest [28, 68], or focally, e.g., due to occlusion of cerebral arteries [69]. Whoever is interested in understanding this process may, for example, watch video 1 by Zhao et al. [69]. This is an illustrative example of how SD in focal cerebral ischemia develops in a single point in the still completely vital tissue in the ischemic core and spreads concentrically from there over the entire hemisphere. The depolarized state induced by this initial SD wave then persists in the core, where it progresses to infarction, while the depolarization recovers and regresses in the non-ischemic cortex. Unfortunately, there is a persistent myth that ischemic infarction in the cortex can develop independent of SD, but this is an outdated understanding and, in view of advances in recent decades, there is no experimental or clinical evidence to support it.
The first scientific evidence that SD comes first and death follows dates back to a 1947 study by Aristides Leão himself [66], who discovered the SD phenomenon in 1944 [70]. The sequence he described has been reproduced many times since then [25, 71] and has been observed in all properly studied animals, from insects to fish and further upwards in phylogenesis. It has now also been confirmed in humans during circulatory arrest, during the development of brain death with continued systemic circulation, and during the development of focal cerebral infarction [25,26,27,28]. The only in vivo exception to the sequence is found under extreme experimental manipulation, when astrocytic function is severely compromised prior to onset of severe ischemia. In this case, the typical sequence of SD followed by cell death is undermined, and cell death may occur in the ischemic core more or less simultaneously with a non-spreading neuronal and astrocytic depolarization [72]. Some may doubt the causal necessity of SD for cell death in vivo on the grounds that neurons die under hypoxia in cell cultures that lack the conditions for SD development. However, in these non-physiologic conditions, neuronal cell death only develops after many hours longer than in vivo [73].
SD is characterized by the near-complete breakdown of the transmembrane ion gradients, cytotoxic edema, and the release of numerous neurotransmitters, including glutamate [74,75,76]. From an electrochemical and thermodynamic perspective, SD refers to the abrupt transition from the physiological double Gibbs-Donnan steady state between intracellular and extracellular space, characterized by low entropy, to a state close to a stable Gibbs-Donnan equilibrium characterized by high entropy [77, 78]. SD is thus the most fundamental electrochemical change that the living brain can experience and represents a disruption in homeostasis that is orders of magnitude greater than that observed, for example, during an epileptic seizure [79,80,81,82]. For a more comprehensive account of the thermodynamic principles of SD, we would like to refer the reader to the following review [75].
SD is measured as a large negative direct current (DC) shift, which can be recorded in humans using a subdural electrode strip and indicates the depolarized state of tissue [59] (Fig. 2). In typical electroencephalography frequency bands (AC-ECoG), SD classically triggers a rapidly developing reduction in the amplitudes of spontaneous activity, known as spreading depression [70] (Fig. 2). However, the changes in neuronal activity that may be associated with SD, even when SD spreads in metabolically intact tissue, are often more complex than just spreading depression [59, 82,83,84]. Measured at the surface of the brain, SD can even lead to an increase in normal brain activity, the so-called “boom” [83]. SD typically propagates in the tissue at a speed between 2 and 9 mm/min [85,86,87]. In certain conditions, however, speeds of up to 15 mm/min have been recorded [88]. For the question of neuronal death or survival during ischemia, the intraneuronal compartment is evidently the most decisive among all cerebral compartments. The term SD describes the abrupt cytotoxic change that leads to edema [74, 89], a more than 100-fold increase in cytoplasmic calcium concentration [67, 90], a three-fold increase in cytoplasmic sodium concentration [91], and a host of other changes in the neuronal cytoplasm that are beyond the scope of this review. Both calcium and sodium are important second messengers [92,93,94]. It is assumed that the extreme deflections of these second messengers alone during SD are highly toxic if they last too long [79, 95].
Typically, the first SD starts in the ischemic core 2 to 5 min after the onset of ischemia [66, 68, 96,97,98,99]. However, depending on the severity of ischemia, latencies of more than 30 min between the onset of ischemia and the first SD have also been described [69]. Importantly, SD does not mark the beginning of cell death but starts the countdown to cell death [71, 79, 100]. If the depolarized state induced by SD persists beyond a threshold duration, the so-called commitment point, the neurons die [95]. This implies that neurons can survive SD in the ischemic core if the tissue is reperfused and repolarizes before the commitment point [25, 71, 101,102,103,104,105,106]. For example, after MCAo in rats, at least 15 min must elapse during which neurons are in the state of SD before the first neurons in the ischemic core begin to die. This means that when the animals are sacrificed 72 h later, no dead neurons are found in the ischemic core if the ischemic core was reperfused within 15 min, even though perfusion was very low and neurons were persistently in the state of SD during the ischemic period (Fig. 4). Generally, the lower the residual blood flow in the ischemic tissue, the shorter is the time until the commitment point is reached [107]. The mechanism of cell death is predominantly necrosis when neurons experience very long-lasting SD of around 30–60 min or longer. This shifts towards apoptosis and, hence, to slower death within the necrotic-apoptotic continuum when there is local reperfusion and recovery from SD after the commitment point but before ~ 30–60 min [102, 108].
Repolarization after SD (reversal of the DC shift) requires activation of energy-dependent membrane pumps such as Na,K-ATPases [79, 109]. Short-lasting DC shifts thus indicate enough ATP at the recording site to fuel repolarization. This feature makes the negative DC shift duration a useful measure for (1) the tissue energy status and (2) the risk of injury at the recording site [59]. Terminal SD is roughly characterized by the initial reversible SD phase followed by the phase of the negative ultraslow potential (NUP) associated with irreversible functional damage [3, 16, 25, 110,111,112]. Terminal SD is observed, for example, when the brain dies as a whole [7, 26,27,28], when the core of a focal ischemic zone dies [25, 112], or when penumbral tissue dies in the further course of infarct maturation [113, 114]. One limitation is that the commitment point can be roughly estimated from the ECoG changes but cannot be precisely determined on ECoG criteria alone. Overall, it is surprisingly difficult to determine the exact point in time at which a loss of function becomes irreversible, even for a single neuron.
The concept of the SD continuum is crucial for clinical neuromonitoring because many SDs observed in patients have intermediate features, as opposed to the two extremes of SD in either severely ischemic or normal tissue [28, 79]. This is relevant not only for the correct bedside reading of ECoGs but also because there are major differences in mechanistic aspects and pharmacological sensitivity of SDs along the continuum. These differences are dictated by local tissue conditions and have implications for the efficacy of therapeutic targeting. Furthermore, although SD is a near-complete breakdown of homeostasis with toxic changes that typically precede ischemic cell death, it is possible that SD could also be adaptive in regions where there is sufficient energy in the tissue to survive it [16, 115]. In this context, it is, for example, interesting that optogenetically triggered SDs outside the ischemic zone in mice did not cause additional ischemic damage [116], in contrast to KCl-triggered SDs outside the ischemic zone in rats [117,118,119]. The optogenetic triggering of SDs is obviously gentler on the tissue than triggering with KCl [79]. A limitation of this murine study is that no direct measurements of SDs were performed, i.e., SDs were neither recorded electrophysiologically nor visualized with, for example, voltage-sensitive dye or calcium imaging, but the rCBF curves shown in Fig. 4 of this study suggest that in the mouse model chosen, only short-lasting SDs were optogenetically triggered [116]. These short-duration SDs did not appear to cause additional damage, which is in good agreement with the above statement that SDs must last longer than 15 min at a given location before irreversible local damage occurs there [25]. Importantly, in contrast to the mouse model of Sugimoto et al. [116], SD clusters with a spontaneous transition from short-duration to long-duration SDs can occur in aSAH patients and, e.g., in MCAO models in rats, typically leading to tissue death at the site of long-duration SDs (for example, compare Fig. 6 in [25], Fig. 7 in [112], Fig. 5 in [111], and Fig. 2 in [113]). This leads to two conclusions: (1) it is important to consider the local duration of SDs to make statements about local progression of damage, while it is not sufficient to simply count SDs [59, 120], and (2) there are conditions under which SDs are harmless [121] or perhaps even beneficial [16, 115]. In this regard, it is interesting to note that SD-like waves occur also in insects and worms [65, 122], and perhaps even in plants, where they are interpreted as a defense mechanism, e.g., when a caterpillar bites into a leaf and the wave spreads over the entire plant [123]. Based on such analogies, SD could perhaps be interpreted as an orderly retreat, which is not a favorable sign, but better than a chaotic collapse of the densely packed cells in most gray matter structures.
However, in mammals, in addition to the initial energy state at the beginning of the wave, neurovascular coupling also plays a key role in determining whether SD is locally harmless or harmful [16]. Thus, in otherwise normal tissue, SD acts as a potent stimulus to increase regional cerebral blood flow (rCBF) (= spreading hyperemia). After repolarization, this increase is typically succeeded by a physiological, prolonged, moderate hypoperfusion (= oligemia) [124, 125]. Under these conditions, neurons survive SD [121]. However, when neurovascular coupling is disturbed, SD can cause severe vasoconstriction instead of vasodilation, resulting in a long-lasting local perfusion deficit that prevents tissue repolarization and can eventually even lead to large cortical infarcts [126, 127]. The electrographic hallmark of this process is the prolonged negative DC shift [126] (Fig. 5). In short, this means that while SD is the usual consequence of cerebral ischemia, it can also be causal in inducing or worsening ischemia [16].
The phenomenon of SD-induced spreading ischemia was originally discovered in a rat model mimicking the conditions after aSAH [126]. On this basis, the first clinical study to detect SDs after aSAH in 2006 provided preliminary evidence that delayed neurological deficits (DND) are associated with a cluster of SDs [5]. The occurrence of SD-induced spreading ischemia was first demonstrated in aSAH patients in 2009 [22]. A translational study from 2017 then showed that focal accumulation of subarachnoid blood is sufficient to trigger SD clusters and early infarcts in a porcine model, and that phenomenologically, nearly identical early neuromonitoring and neuroimaging findings also occur in aSAH patients [3]. Using neuromonitoring technology in combination with longitudinal neuroimaging, the entire sequence of early and delayed brain infarct development following aSAH was shown in 2018 in a small patient population. In sum, recordings from optoelectrodes located directly over newly developing infarcts demonstrated SD-induced persistent activity depression, SD-induced spreading ischemia, and the transition from clustered SDs to NUP [25]. In the same year, the first clinical drug trial targeting SD-induced spreading ischemia was published [128]. The study investigated the endothelial nitric oxide synthase (NOS) activator cilostazol and showed a trend towards less DCI in the treatment group. Accordingly, the total duration of SD-induced depression per recording day was significantly lower in the cilostazol group. These associations were later confirmed in 2022 when the DISCHARGE-1 study found that SD variables contributed to every multiple regression model of early, delayed, and total brain damage after aSAH (and also patient outcome and death), strongly suggesting that they are an independent biomarker of progressive brain injury [7]. SDs were not only significantly associated with the evolution of delayed brain infarcts in this study, but also with reversible DNDs, which in clinical parlance are most closely equated with transient ischemic attacks (TIA). In contrast, the typical symptoms of a migraine aura in connection with an ECoG-recorded SD were actually only noticed in one aSAH patient in a total of over 200 patients with several thousand SDs [60]. In this one patient, however, there was a clear temporal connection with SD in two consecutive aura episodes.
In 2023, Horst et al. [10] then demonstrated that SD variables are a statistical mediator between subarachnoid blood volume and delayed infarct volume, while angiographic vasospasm is a mediator between intraventricular blood volume and delayed infarct volume in aSAH patients. However, no correlation was found between SD variables and angiographic vasospasm. Although there are hypotheses [3, 16, 129], the exact mechanism by which many SDs develop in patients with severe aSAH remains a mystery. The cause of SDs could well be multifactorial. However, we consider it likely that there is a principal pathogenesis axis in the development of cortical infarcts after aSAH [3, 8,9,10,11,12,13,14] that originates from toxic subarachnoid blood products [20, 130,131,132] and leads to SD-induced spreading ischemia via (1) mechanisms of SD initiation and (2) altered vasoreactivity in the cortical microcirculation [16, 126], with (3) mechanisms of local neuroinflammation probably also involved [133, 134]. SD-induced spreading ischemia would then in turn lead to the development of infarction if it causes the depolarized state to persist beyond the commitment point. In our opinion, proximal vasospasm is not a necessary prerequisite for the development of this pathophysiologic cascade (Fig. 3b) [4, 7, 135,136,137,138,139]. However, the statistical results in the DISCHARGE-1 population [7, 10] and animal data [140, 141] suggest that proximal vasospasm may enhance the processes in the neurovascular unit that lead to the development of cortical infarcts after aSAH.
Neuromonitoring-Based Detection of DCI
In DISCHARGE-1, the best real-time predictor of DCI in the hemisphere equipped with the subdural electrode strip was the peak total SD-induced depression duration of a recording day (PTDDD) during the delayed neuromonitoring period (PTDDDdelayed) [7] (Fig. 2). This variable is explained in detail in the COSBID recommendations [59] and denotes the time in minutes in which the most severely affected ECoG channel was in a state of SD-induced depression of spontaneous activity during a recording day. The maximum possible value of PTDDDdelayed is 1440 min, as a day has 1440 min. The area under the receiver operating characteristic curve (AUROC) of PTDDDdelayed was 0.76 (95% CI, 0.69–0.83; p < 0.001) for delayed infarction ipsilateral to the recording strip and 0.88 (95% CI, 0.81–0.94; p < 0.001) for DCI (reversible DND or infarction) [7]. For comparison, the AUROC of angiographic vasospasm (digital subtraction angiography (DSA) score of the hemisphere ipsilateral to the subdural electrode strip [7]) was only 0.64 (95% CI, 0.54–0.74; p = 0.009) for ipsilateral delayed cerebral infarction and 0.68 (95% CI, 0.54–0.82; p = 0.016) for DCI. Peak transcranial Doppler-sonography-(TCD)-determined mean blood flow velocities of the basal cerebral arteries had a similar value for the prediction of delayed infarction and DCI as DSA [7, 10] (Fig. 3b). In multivariate analysis, PTDDDdelayed (β = 0.474, p < 0.001), delayed median Glasgow Coma Score (GCS) (β = − 0.201, p = 0.005), and peak TCD-determined mean blood flow velocity of the ipsilateral MCA (β = 0.169, p = 0.016) explained 35% of the variance in delayed infarction.
In the discussion of Dreier et al. [7], it was suggested how PTDDDdelayed may serve to detect reversible neurological deficits and impending infarcts, particularly in unconscious patients, to identify in real-time aSAH patients who are most likely to benefit from targeted management strategies. Thus, a 25-min cut-off for PTDDDdelayed seems to be an appropriate first “alert level” to review the patient’s status and initiate tier 1 of targeted management strategies. This recommendation was made although it is still relatively uncertain after 25 min whether the event will be reversible or progress to infarction. It was suggested that tier 1 management adjusts targets for physiological interventions that are expected to modulate the development of SD, such as physiological variables like mean arterial pressure (MAP). If the cumulative SD-induced depression duration of the most recent 24-h period has then exceeded 180 min, the patient has developed a new infarct with 0.62 sensitivity and 0.83 specificity, implying that rescue therapy should not wait 180 min. Therefore, a 60-min cut-off was proposed as an appropriate moment to initiate rescue therapy because it indicates still reversible DND with 0.71 sensitivity and 0.82 specificity. However, ultimately the time delay before starting a therapy is likely to be longer if the intervention has potentially serious side effects than if it has comparatively few side effects. In addition, it was pointed out that automated analysis techniques are under development and will be important in practice if real-time ECoG recordings are used to inform treatment decisions. However, even when such automated analysis techniques are established, it will still be relevant for intensivists to be able to check critical ECoG patterns on the monitor.
Unfortunately, there are a number of pitfalls that can lead to SDs and newly developing infarcts being missed in electrographic recordings. Most of these pitfalls have to do with inadequate recording technique. Figure 3a illustrates one of these pitfalls, namely the loss of information when using subdural recordings that are near-DC, as opposed to full-band DC [22] (a graphical explanation of the technical difference between near-DC and full-band DC recordings can be found in Fig. 1 in Dreier et al. [59]). Attempts to measure SDs with typical intraparenchymal electrode arrays [59, 142,143,144], epidural electrodes [27], or scalp electrodes [111, 145, 146] are associated with an even greater loss of significance. For example, when intraparenchymal or epidural electrodes are used, around 50% of SDs remain undetected [27, 142]. The DC amplitudes of SDs in epidural recordings are 4 times smaller [27], and in the scalp EEG, they are even 30 times smaller [147] than in the subdural ECoG. In particular, caution is required if signals, e.g., in the scalp EEG, are superficially reminiscent of SDs, but the potential changes are not verified as SDs with parallel subdural ECoG recordings [148]. Since the pattern of true SDs in scalp EEG verified with simultaneous subdural DC/AC-ECoG has already been described [111, 145], it makes sense to first compare one’s own recordings with this pattern before publishing phenomena as SDs that may not be SDs. Overall, electrographic recordings are unfortunately characterized not only by a great abundance of biological events, but also by non-biological artifacts [149].
Those who want to base clinical decisions on neuromonitoring should use meaningful methods and, as far as SDs are concerned, this is so far only the subdural DC/AC-ECoG (cf. Figures 2, 3, 5, and 6) [59]. With regard to patient safety, linear subdural electrodes, in contrast to electrode grids (which are only used in preoperative epilepsy diagnostics [150]), are not associated with significant complications [7, 29, 32, 128, 151,152,153,154,155] if the recommendations for neurosurgical implantation are followed [156]. In addition, in contrast to intraparenchymal probes [157], linear subdural electrodes do not cause parenchymal injury or local dysfunction of the blood–brain barrier (BBBD), as evidenced with longitudinal MRIs in DISCHARGE-1 [7]. Interesting recent developments include the placement of a slimmer Spencer array subdurally via a burr hole [23, 24] instead of a Wyler electrode strip [22] in patients who do not require a craniotomy. Since an electrode strip can only detect DCI in the hemisphere on which it is placed, this is also a promising way of conducting neuromonitoring of both hemispheres.
Development of Brain Death During Continued Circulation After aSAH and TBI
The electrographic processes that occur during death are closely related to those that occur during the development of brain infarction. Basically, there are two different biological pathways that lead to the death of the brain: death during cardiocirculatory arrest and brain death during continued systemic circulation. Terminal SD is the electrographic hallmark of both processes. The first study showing terminal SD after cardiocirculatory arrest in patients with aSAH or TBI was published in 2018 [28], closely followed by the first studies showing the characteristic pattern of development of brain death during continued systemic circulation in aSAH patients during neurocritical care [26, 27]. In cardiocirculatory death of patients, as in animals, a simultaneous silencing of neuronal activity (non-spreading depression) develops first, followed by terminal SD with a latency of between 13 and 266 s. In brain death during continued systemic circulation, by contrast, there is a cluster of SDs that can initiate the neuronal silencing in the form of spreading depression, and the SDs eventually transition to a terminal SD characterized by the NUP. The development of ICP increase in the wake of the SD cluster before the development of brain death during continued systemic circulation was then first demonstrated in a DISCHARGE-1 patient [7]. Figures 5 and 7 show two further examples.
Recent experimental evidence suggests that the development of malignant edema with a fatal increase in ICP is at least partly a consequence of SDs [89, 158]. During SD, the concentration gradients of the major ions across the neuronal membranes almost completely collapse (e.g., the intraneuronal calcium concentration increases more than 100-fold and water flows into the neurons (cytotoxic edema)), yet myriads of other small molecules also change their distribution between intra- and extracellular space [67, 75, 90]. Along with the cytotoxic edema caused by SD, an increased content of sodium and chloride ions and water then gradually develops in the tissue if the SD-induced shifts between the intracellular and extracellular space persist [89, 159]. This so-called ionic interstitial edema can be life-threatening because it can increase ICP [89, 160]. Experimentally, cerebrospinal fluid (CSF) surrounding the brain has been identified as the source of ionic edema by penetrating the tissue through perivascular flow channels. This process is initiated by SDs and also by SD-induced spreading ischemia, which further enlarges perivascular spaces and doubles glymphatic inflow speeds [158]. Figure 5 shows a striking example of SD in a patient with aSAH from the DISCHARGE-1 population that triggered spreading ischemia and preceded a terminal crisis of ICP leading to brain death. Figure 6 provides another example of brain death development after aSAH. In this case, a terminal SD cluster resulted from brainstem compression 36 h before circulatory arrest. Figure 7 shows a terminal SD cluster during the development of brain death in a patient with TBI. As expected, the electrographic pattern of brain death development after TBI appears to be very similar to that after aSAH. However, only near-DC/AC-ECoG recordings and no full-band DC/AC-ECoG recordings were available in this patient, which somewhat limits the interpretation, as already explained in Fig. 3a. Of particular interest in Fig. 7 are pulse artifacts in the ECoG of increasingly high amplitude, which seem to occur in association with the SDs, at least in part, and are most likely to be interpreted as an expression of decreased tissue elasticity and increased pulse pressure in the course of brain edema development [64, 82, 161]. SDs were also shown to activate caveolin-1-mediated transport across the BBB [162]. SDs could therefore also contribute to the development of brain edema and ICP increase via BBBD [163]. However, the development of the BBBD-initiated vasogenic interstitial edema is assumed to take several hours longer than the development of the glymphatic system-mediated ionic interstitial edema [89]. Whether these processes can be favorably influenced by drugs that target SDs, such as N-methyl-D-aspartate receptor (NMDAR) antagonists, is currently the subject of intensive preclinical and clinical research [164,165,166,167,168,169,170].
Conclusions
Timely diagnosis of DCI is a serious clinical problem. While physicians can usually recognize acute disturbances of the brain’s energy metabolism in a fully conscious patient through the medical history and neurological examination [59, 171], patients with severe aSAH are often comatose for long periods of time due to the initial injury and sedatives, and the intensivist has little chance of recognizing new neurological deficits against the background of the pre-existing global neurological deficit. Therefore, diagnosis of DCI is usually delayed in the critical care setting, and rescue treatment cannot be provided at the appropriate time. In DISCHARGE-1, for example, 90/170 of the early survivors (52.9%) were clinically unassessable during the entire observation period of 2 weeks. To make matters worse, these comatose patients also had a significantly larger delayed infarct volume than patients for whom clinical assessment was at least partially feasible [7].
In this regard, regional ECoG monitoring offers a significant advantage since it allows local and even remote detection of developing DCI. This is due to the fact that SDs propagate widely from metabolically stressed zones and characteristic patterns, including temporal clusters of SDs and persistent depression of spontaneous brain activity, can be recognized and quantified. The spread of SDs and the widespread changes in spontaneous activity that they entail is a particular advantage of ECoG over other neuromonitoring modalities, such as microdialysis or brain tissue partial pressure of oxygen measurements, which record only local conditions and may not detect clinically important changes that develop elsewhere in an injured lobe or hemisphere [10].
Other techniques for predicting DCI are, for example, perfusion CT or perfusion MRI. Positron emission tomography (PET), unlike perfusion CT and perfusion MRI, even allows absolute measurements of rCBF. However, none of these techniques allows continuous measurements in real time, and concerning PET, the most informative among these imaging modalities, Minhas et al. [136] concluded the following: “A markedly heterogeneous pattern of CBF distribution was observed, with hyperemia, normal CBF values, and reduced flow being observed among patients with delayed neurological deficits… Among patients who developed delayed neurological deficits after aneurysmal subarachnoid hemorrhage, a wide range of cerebral perfusion disturbances was observed, calling into question the traditional concept of large-vessel vasospasm.” These PET observations fit perfectly with the invasively measured neuromonitoring data, in which the course of rCBF in patients with DCI was highly dynamic. Thus, in SD-induced spreading ischemia, rCBF typically falls locally from sometimes quite high to ischemic values within seconds and may remain in the ischemic range for up to 2.5 h [22]. After the ischemic phase, rCBF may rise to extremely high levels, well above the initial baseline, to gradually return to normal or somewhat reduced levels over several tens of minutes until the next SD-induced spreading ischemia occurs (for example, compare Fig. 7 in [22]) or Fig. 6 in [25]). Accordingly, the neuromonitoring methods discussed here have enormous potential, as they map these highly dynamic changes in real time and with greater accuracy than previous methods. Only the development of adequate diagnostic procedures for the timely detection of patients in need of therapy offers the chance to identify patients who could benefit from a given treatment and selectively treat them at the right time; meanwhile, the remaining patients without such complications could be spared the side effects of unnecessary interventions. It would therefore be a fallacy to use the current lack of evidence-based rescue therapies for DCI [20, 172] as an argument for not developing precision medicine for DCI. The lack of such therapies is only a logical consequence of the lack of appropriate diagnostic methods. The advances in neuromonitoring and understanding of brain lesion development, as outlined here, offer hope that precision medicine for aSAH and similar acute neurologic diseases can still be achieved.
Data Availability
Electronic recording, processing and storage of the data were approved by the data protection officer of the Charité – Universitätsmedizin Berlin (data protection votes from 28 May 2008 and 5 May 2014). The datasets analyzed are not publicly available because the patient’s informed consent only permits the data analysis and publication by the investigators.
Abbreviations
- AC:
-
Alternating current
- aSAH:
-
Aneurysmal subarachnoid hemorrhage
- AUROC:
-
Area under the receiver operating characteristic curve
- BBB:
-
Blood-brain barrier
- BBBD:
-
Blood-brain barrier dysfunction
- CBF:
-
Cerebral blood flow
- 95% CI:
-
95% Confidence interval
- COSBID:
-
Co-Operative Studies on Brain Injury Depolarizations
- CT:
-
Computed tomography
- DALY:
-
Disability-adjusted life years
- DC:
-
Direct current
- DCI:
-
Delayed cerebral ischemia
- DISCHARGE-1:
-
Depolarizations in ischemia after subarachnoid hemorrhage-1
- DND:
-
Delayed neurological deficit
- DSA:
-
Digital subtraction angiography
- ECI:
-
Early cerebral ischemia
- ECoG:
-
Electrocorticography
- GCS:
-
Glasgow Coma Score
- ICH:
-
Intracerebral hemorrhage
- ICP:
-
Intracranial pressure
- IQR:
-
Interquartile range
- MAP:
-
Mean arterial blood pressure
- MCA:
-
Middle cerebral artery
- MCAo:
-
Middle cerebral artery occlusion
- MRI:
-
Magnetic resonance imaging
- NMDAR:
-
N-methyl-D-aspartate receptor
- NOS:
-
Nitric oxide synthase
- NUP:
-
Negative ultraslow potential
- PET:
-
Positron emission tomography
- PTDDD:
-
Peak total spreading depolarization-induced depression duration of a recording day
- PTDDDdelayed :
-
Peak total spreading depolarization-induced depression duration of a recording day in the delayed neuromonitoring period
- SAH:
-
Subarachnoid hemorrhage
- SD:
-
Spreading depolarization
- TBI:
-
Traumatic brain injury
- TCD:
-
Transcranial Doppler-sonography
- TIA:
-
Transient ischemic attack
- tSAH:
-
Traumatic subarachnoid hemorrhage
- YPLL:
-
Proportion of potential years of life lost before age 65
References
Sarrafzadeh AS, Sakowitz OW, Kiening KL, Benndorf G, Lanksch WR, Unterberg AW. Bedside microdialysis: a tool to monitor cerebral metabolism in subarachnoid hemorrhage patients? Crit Care Med. 2002;30(5):1062–70.
Wartenberg KE, Sheth SJ, Michael Schmidt J, Frontera JA, Rincon F, Ostapkovich N, et al. Acute ischemic injury on diffusion-weighted magnetic resonance imaging after poor grade subarachnoid hemorrhage. Neurocrit Care. 2011;14(3):407–15. https://doi.org/10.1007/s12028-010-9488-1.
Hartings JA, York J, Carroll CP, Hinzman JM, Mahoney E, Krueger B, et al. Subarachnoid blood acutely induces spreading depolarizations and early cortical infarction. Brain. 2017;140(10):2673–90. https://doi.org/10.1093/brain/awx214.
Vergouwen MD, Vermeulen M, van Gijn J, Rinkel GJ, Wijdicks EF, Muizelaar JP, et al. Definition of delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage as an outcome event in clinical trials and observational studies: proposal of a multidisciplinary research group. Stroke. 2010;41(10):2391–5 (STROKEAHA.110.589275 [pii] 10.1161).
Dreier JP, Woitzik J, Fabricius M, Bhatia R, Major S, Drenckhahn C, et al. Delayed ischaemic neurological deficits after subarachnoid haemorrhage are associated with clusters of spreading depolarizations. Brain. 2006;129(Pt 12):3224–37. https://doi.org/10.1093/brain/awl297.
Birse SH, Tom MI. Incidence of cerebral infarction associated with ruptured intracranial aneurysms. A study of 8 unoperated cases of anterior cerebral aneurysm. Neurology. 1960;10:101–6.
Dreier JP, Winkler MKL, Major S, Horst V, Lublinsky S, Kola V, et al. Spreading depolarizations in ischaemia after subarachnoid haemorrhage, a diagnostic phase III study. Brain. 2022;145(4):1264–84. https://doi.org/10.1093/brain/awab457.
Rabinstein AA, Weigand S, Atkinson JL, Wijdicks EF. Patterns of cerebral infarction in aneurysmal subarachnoid hemorrhage. Stroke. 2005;36(5):992–7. https://doi.org/10.1161/01.STR.0000163090.59350.5a.
Dreier JP, Sakowitz OW, Harder A, Zimmer C, Dirnagl U, Valdueza JM, Unterberg AW. Focal laminar cortical MR signal abnormalities after subarachnoid hemorrhage. Ann Neurol. 2002;52(6):825–9. https://doi.org/10.1002/ana.10383.
Horst V, Kola V, Lemale CL, Major S, Winkler MKL, Hecht N, et al. Spreading depolarization and angiographic spasm are separate mediators of delayed infarcts. Brain Commun. 2023;5(2):fcad080. https://doi.org/10.1093/braincomms/fcad080.
Schatlo B, Dreier JP, Glasker S, Fathi AR, Moncrief T, Oldfield EH, et al. Report of selective cortical infarcts in the primate clot model of vasospasm after subarachnoid hemorrhage. Neurosurgery. 2010;67(3):721–9. https://doi.org/10.1227/01.NEU.0000378024.70848.8F.
Stoltenburg-Didinger G, Schwarz K. Brain lesions secondary to subarachnoid hemorrhage due to ruptured aneurysms. In: Cervós-Navarro J, Ferszt R, editors. Stroke and microcirculation. New York: Raven Press; 1987. p. 471–80.
Neil-Dwyer G, Lang DA, Doshi B, Gerber CJ, Smith PW. Delayed cerebral ischaemia: the pathological substrate. Acta Neurochir (Wien). 1994;131(1–2):137–45.
Weidauer S, Vatter H, Beck J, Raabe A, Lanfermann H, Seifert V, Zanella F. Focal laminar cortical infarcts following aneurysmal subarachnoid haemorrhage. Neuroradiology. 2008;50(1):1–8. https://doi.org/10.1007/s00234-007-0294-1.
Qureshi AI, Wilson DA, Hanley DF, Traystman RJ. No evidence for an ischemic penumbra in massive experimental intracerebral hemorrhage. Neurology. 1999;52(2):266–72. https://doi.org/10.1212/wnl.52.2.266.
Dreier JP. The role of spreading depression, spreading depolarization and spreading ischemia in neurological disease. Nat Med. 2011;17(4):439–47. https://doi.org/10.1038/nm.2333.
Goyal M, Menon BK, van Zwam WH, Dippel DW, Mitchell PJ, Demchuk AM, et al. Endovascular thrombectomy after large-vessel ischaemic stroke: a meta-analysis of individual patient data from five randomised trials. Lancet. 2016;387(10029):1723–31. https://doi.org/10.1016/S0140-6736(16)00163-X.
Emberson J, Lees KR, Lyden P, Blackwell L, Albers G, Bluhmki E, et al. Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials. Lancet. 2014;384(9958):1929–35. https://doi.org/10.1016/S0140-6736(14)60584-5.
Saver JL. Time is brain–quantified. Stroke. 2006;37(1):263–6. https://doi.org/10.1161/01.STR.0000196957.55928.ab.
Macdonald RL, Schweizer TA. Spontaneous subarachnoid haemorrhage. Lancet. 2017;389(10069):655–66. https://doi.org/10.1016/S0140-6736(16)30668-7.
Disease NNRCCoaFfDaNTo. Toward precision medicine: building a knowledge network for biomedical research and a new taxonomy of disease. Washington, DC: The National Academies Press; 2011.
Dreier JP, Major S, Manning A, Woitzik J, Drenckhahn C, Steinbrink J, et al. Cortical spreading ischaemia is a novel process involved in ischaemic damage in patients with aneurysmal subarachnoid haemorrhage. Brain. 2009;132(Pt 7):1866–81. https://doi.org/10.1093/brain/awp102.
Meinert F, Dömer P, Helgers SOA, Schumm L, Hecht N, Dreier JP, Woitzik J. Subdural placement of electrocorticographic electrode array through a burr hole exposure: 2-dimensional operative video. Oper Neurosurg. 2022. https://doi.org/10.1227/ons.0000000000000299.
Meinert F, Lemale CL, Major S, Helgers SOA, Domer P, Mencke R, et al. Less-invasive subdural electrocorticography for investigation of spreading depolarizations in patients with subarachnoid hemorrhage. Front Neurol. 2022;13:1091987. https://doi.org/10.3389/fneur.2022.1091987.
Luckl J, Lemale CL, Kola V, Horst V, Khojasteh U, Oliveira-Ferreira AI, et al. The negative ultraslow potential, electrophysiological correlate of infarction in the human cortex. Brain. 2018;141(6):1734–52. https://doi.org/10.1093/brain/awy102.
Carlson AP, Shuttleworth CW, Major S, Lemale CL, Dreier JP, Hartings JA. Terminal spreading depolarizations causing electrocortical silencing prior to clinical brain death: case report. J Neurosurg. 2019;131(6):1773–9. https://doi.org/10.3171/2018.7.JNS181478.
Dreier JP, Major S, Lemale CL, Kola V, Reiffurth C, Schoknecht K, et al. Correlates of spreading depolarization, spreading depression, and negative ultraslow potential in epidural versus subdural electrocorticography. Front Neurosci. 2019;13:373. https://doi.org/10.3389/fnins.2019.00373.
Dreier JP, Major S, Foreman B, Winkler MKL, Kang EJ, Milakara D, et al. Terminal spreading depolarization and electrical silence in death of human cerebral cortex. Ann Neurol. 2018;83(2):295–310. https://doi.org/10.1002/ana.25147.
Hartings JA, Andaluz N, Bullock MR, Hinzman JM, Mathern B, Pahl C, et al. Prognostic value of spreading depolarizations in patients with severe traumatic brain injury. JAMA Neurol. 2020;77(4):489–99. https://doi.org/10.1001/jamaneurol.2019.4476.
Hartings JA, Bullock MR, Okonkwo DO, Murray LS, Murray GD, Fabricius M, et al. Spreading depolarisations and outcome after traumatic brain injury: a prospective observational study. Lancet Neurol. 2011;10(12):1058–64. https://doi.org/10.1016/S1474-4422(11)70243-5.
Strong AJ, Fabricius M, Boutelle MG, Hibbins SJ, Hopwood SE, Jones R, et al. Spreading and synchronous depressions of cortical activity in acutely injured human brain. Stroke. 2002;33(12):2738–43.
Fabricius M, Fuhr S, Bhatia R, Boutelle M, Hashemi P, Strong AJ, Lauritzen M. Cortical spreading depression and peri-infarct depolarization in acutely injured human cerebral cortex. Brain. 2006;129(Pt 3):778–90. https://doi.org/10.1093/brain/awh716. (awh716 [pii]).
Schinke C, Horst V, Schlemm L, Wawra M, Scheel M, Hartings JA, Dreier JP. A case report of delayed cortical infarction adjacent to sulcal clots after traumatic subarachnoid hemorrhage in the absence of proximal vasospasm. BMC Neurol. 2018;18(1):210. https://doi.org/10.1186/s12883-018-1217-y.
Riemann L, Mikolic A, Maas A, Unterberg A, Younsi A. Collaborative European neurotrauma effectiveness research in traumatic brain injury I, participants. Computed tomography lesions and their association with global outcome in young people with mild traumatic brain injury. J Neurotrauma. 2023;40(11–12):1243–54. https://doi.org/10.1089/neu.2022.0055.
Hinzman JM, Andaluz N, Shutter LA, Okonkwo DO, Pahl C, Strong AJ, et al. Inverse neurovascular coupling to cortical spreading depolarizations in severe brain trauma. Brain. 2014;137(Pt 11):2960–72. https://doi.org/10.1093/brain/awu241.
Perrein A, Petry L, Reis A, Baumann A, Mertes P, Audibert G. Cerebral vasospasm after traumatic brain injury: an update. Minerva Anestesiol. 2015;81(11):1219–28.
Desai M, Morris NA. Prolonged post-traumatic vasospasm resulting in delayed cerebral ischemia after mild traumatic brain injury. Neurocrit Care. 2018;29(3):512–8. https://doi.org/10.1007/s12028-018-0542-8.
Collaborators GBDLRoS, Feigin VL, Nguyen G, Cercy K, Johnson CO, Alam T, et al. Global, regional, and country-specific lifetime risks of stroke, 1990 and 2016. N Engl J Med. 2018;379(25):2429–37. https://doi.org/10.1056/NEJMoa1804492.
van Asch CJ, Luitse MJ, Rinkel GJ, van der Tweel I, Algra A, Klijn CJ. Incidence, case fatality, and functional outcome of intracerebral haemorrhage over time, according to age, sex, and ethnic origin: a systematic review and meta-analysis. Lancet Neurol. 2010;9(2):167–76. https://doi.org/10.1016/S1474-4422(09)70340-0.
Sacco S, Marini C, Toni D, Olivieri L, Carolei A. Incidence and 10-year survival of intracerebral hemorrhage in a population-based registry. Stroke. 2009;40(2):394–9. https://doi.org/10.1161/STROKEAHA.108.523209.
Flaherty ML, Woo D, Haverbusch M, Sekar P, Khoury J, Sauerbeck L, et al. Racial variations in location and risk of intracerebral hemorrhage. Stroke. 2005;36(5):934–7. https://doi.org/10.1161/01.STR.0000160756.72109.95.
Etminan N, Chang HS, Hackenberg K, de Rooij NK, Vergouwen MDI, Rinkel GJE, Algra A. Worldwide incidence of aneurysmal subarachnoid hemorrhage according to region, time period, blood pressure, and smoking prevalence in the population: a systematic review and meta-analysis. JAMA Neurol. 2019;76(5):588–97. https://doi.org/10.1001/jamaneurol.2019.0006.
Uhl C, Huscher D, Sommerfeld J, Schonberg B, Vajkoczy P, Dengler NF. Aneurysmal subarachnoid hemorrhage in Germany between 2005 and 2018: a nationwide observational study. Eur J Neurol. 2022;29(10):3009–16. https://doi.org/10.1111/ene.15457.
de Rooij NK, Linn FH, van der Plas JA, Algra A, Rinkel GJ. Incidence of subarachnoid haemorrhage: a systematic review with emphasis on region, age, gender and time trends. J Neurol Neurosurg Psychiatry. 2007;78(12):1365–72. https://doi.org/10.1136/jnnp.2007.117655.
Nieuwkamp DJ, Setz LE, Algra A, Linn FH, de Rooij NK, Rinkel GJ. Changes in case fatality of aneurysmal subarachnoid haemorrhage over time, according to age, sex, and region: a meta-analysis. Lancet Neurol. 2009;8(7):635–42. https://doi.org/10.1016/S1474-4422(09)70126-7.
Connolly ES Jr, Rabinstein AA, Carhuapoma JR, Derdeyn CP, Dion J, Higashida RT, et al. Guidelines for the management of aneurysmal subarachnoid hemorrhage: a guideline for healthcare professionals from the American Heart Association/american Stroke Association. Stroke. 2012;43(6):1711–37. https://doi.org/10.1161/STR.0b013e3182587839.
Johnston SC, Selvin S, Gress DR. The burden, trends, and demographics of mortality from subarachnoid hemorrhage. Neurology. 1998;50(5):1413–8.
Malhotra K, Zompola C, Theodorou A, Katsanos AH, Shoamanesh A, Gupta H, et al. Prevalence, characteristics, and outcomes of undetermined intracerebral hemorrhage: a systematic review and meta-analysis. Stroke. 2021;52(11):3602–12. https://doi.org/10.1161/STROKEAHA.120.031471.
Appelros P, Stegmayr B, Terent A. Sex differences in stroke epidemiology: a systematic review. Stroke. 2009;40(4):1082–90. https://doi.org/10.1161/STROKEAHA.108.540781.
Rosen DS, Macdonald RL. Grading of subarachnoid hemorrhage: modification of the world World Federation of Neurosurgical Societies scale on the basis of data for a large series of patients. Neurosurgery. 2004;54(3):566–75 (discussion 75-6.).
Ronne-Engstrom E, Alexanderson K, Friberg E. Sickness absence, disability pension and economic situation after a spontaneous subarachnoid haemorrhage among people of working age: a Swedish longitudinal nationwide cohort study. BMJ Open. 2021;11(1):e040941. https://doi.org/10.1136/bmjopen-2020-040941.
Mirin AA. Gender disparity in the funding of diseases by the U.S. National Institutes of Health. J Womens Health (Larchmt). 2021;30(7):956–63. https://doi.org/10.1089/jwh.2020.8682.
Lovelock CE, Rinkel GJ, Rothwell PM. Time trends in outcome of subarachnoid hemorrhage: population-based study and systematic review. Neurology. 2010;74(19):1494–501. https://doi.org/10.1212/WNL.0b013e3181dd42b3.
Martin E. Sind Fortschritte in der Intensivmedizin noch finanzierbar. Anästh Intensivbehand. 1998;2:1–9.
Reardon PM, Fernando SM, Van Katwyk S, Thavorn K, Kobewka D, Tanuseputro P, et al. Characteristics, outcomes, and cost patterns of high-cost patients in the intensive care unit. Crit Care Res Pract. 2018;2018:5452683. https://doi.org/10.1155/2018/5452683.
Rivero-Arias O, Gray A, Wolstenholme J. Burden of disease and costs of aneurysmal subarachnoid haemorrhage (aSAH) in the United Kingdom. Cost Eff Resour Alloc. 2010;8:6. https://doi.org/10.1186/1478-7547-8-6.
Rigante L, van Lieshout JH, Vergouwen MDI, van Griensven CHS, Vart P, van der Loo L, et al. Time trends in the risk of delayed cerebral ischemia after subarachnoid hemorrhage: a meta-analysis of randomized controlled trials. Neurosurg Focus. 2022;52(3):E2. https://doi.org/10.3171/2021.12.FOCUS21473.
Escudero D, Valentin MO, Escalante JL, Sanmartin A, Perez-Basterrechea M, de Gea J, et al. Intensive care practices in brain death diagnosis and organ donation. Anaesthesia. 2015;70(10):1130–9. https://doi.org/10.1111/anae.13065.
Dreier JP, Fabricius M, Ayata C, Sakowitz OW, William Shuttleworth C, Dohmen C, et al. Recording, analysis, and interpretation of spreading depolarizations in neurointensive care: Review and recommendations of the COSBID research group. J Cereb Blood Flow Metab. 2017;37(5):1595–625. https://doi.org/10.1177/0271678X16654496.
Major S, Huo S, Lemale CL, Siebert E, Milakara D, Woitzik J, et al. Direct electrophysiological evidence that spreading depolarization-induced spreading depression is the pathophysiological correlate of the migraine aura and a review of the spreading depolarization continuum of acute neuronal mass injury. Geroscience. 2020;42(1):57–80. https://doi.org/10.1007/s11357-019-00142-7.
Leão AAP, Morison RS. Propagation of spreading cortical depression. J Neurophysiol. 1945;8:33–45.
Lauritzen M, Olesen J. Regional cerebral blood flow during migraine attacks by Xenon-133 inhalation and emission tomography. Brain. 1984;107(Pt 2):447–61. https://doi.org/10.1093/brain/107.2.447.
Hadjikhani N, Sanchez Del Rio M, Wu O, Schwartz D, Bakker D, Fischl B, et al. Mechanisms of migraine aura revealed by functional MRI in human visual cortex. Proc Natl Acad Sci U S A. 2001;98(8):4687–92. https://doi.org/10.1073/pnas.071582498071582498.
Oliveira-Ferreira AI, Major S, Przesdzing I, Kang EJ, Dreier JP. Spreading depolarizations in the rat endothelin-1 model of focal cerebellar ischemia. J Cereb Blood Flow Metab. 2020;40(6):1274–89. https://doi.org/10.1177/0271678X19861604.
Spong KE, Dreier JP, Robertson RM. A new direction for spreading depolarization: Investigation in the fly brain. Channels (Austin). 2017;11(2):97–8. https://doi.org/10.1080/19336950.2016.1239898.
Leão AAP. Further observations on the spreading depression of activity in the cerebral cortex. J Neurophysiol. 1947;10(6):409–14.
Revah O, Lasser-Katz E, Fleidervish IA, Gutnick MJ. The earliest neuronal responses to hypoxia in the neocortical circuit are glutamate-dependent. Neurobiol Dis. 2016;95:158–67. https://doi.org/10.1016/j.nbd.2016.07.019.
Farkas E, Bari F, Obrenovitch TP. Multi-modal imaging of anoxic depolarization and hemodynamic changes induced by cardiac arrest in the rat cerebral cortex. Neuroimage. 2010;51(2):734–42. https://doi.org/10.1016/j.neuroimage.2010.02.055.
Zhao HT, Tuohy MC, Chow D, Kozberg MG, Kim SH, Shaik MA, Hillman EMC. Neurovascular dynamics of repeated cortical spreading depolarizations after acute brain injury. Cell Rep. 2021;37(1):109794. https://doi.org/10.1016/j.celrep.2021.109794.
Leão AAP. Spreading depression of activity in the cerebral cortex. J Neurophysiol. 1944;7:359–90.
Nozari A, Dilekoz E, Sukhotinsky I, Stein T, Eikermann-Haerter K, Liu C, et al. Microemboli may link spreading depression, migraine aura, and patent foramen ovale. Ann Neurol. 2010;67(2):221–9. https://doi.org/10.1002/ana.21871.
Menyhart A, Frank R, Farkas AE, Sule Z, Varga VE, Nyul-Toth A, et al. Malignant astrocyte swelling and impaired glutamate clearance drive the expansion of injurious spreading depolarization foci. J Cereb Blood Flow Metab. 2022;42(4):584–99. https://doi.org/10.1177/0271678X211040056.
Niquet J, Baldwin RA, Allen SG, Fujikawa DG, Wasterlain CG. Hypoxic neuronal necrosis: protein synthesis-independent activation of a cell death program. Proc Natl Acad Sci U S A. 2003;100(5):2825–30. https://doi.org/10.1073/pnas.0530113100.
Kirov SA, Fomitcheva IV, Sword J. Rapid neuronal ultrastructure disruption and recovery during spreading depolarization-induced cytotoxic edema. Cereb Cortex. 2020;30(10):5517–31. https://doi.org/10.1093/cercor/bhaa134.
Lemale CL, Luckl J, Horst V, Reiffurth C, Major S, Hecht N, et al. Migraine Aura, Transient ischemic attacks, stroke, and dying of the brain share the same key pathophysiological process in neurons driven by Gibbs-Donnan forces, namely spreading depolarization. Front Cell Neurosci. 2022;16:837650. https://doi.org/10.3389/fncel.2022.837650.
Andrew RD, Farkas E, Hartings JA, Brennan KC, Herreras O, Muller M, et al. Questioning glutamate excitotoxicity in acute brain damage: the importance of spreading depolarization. Neurocrit Care. 2022. https://doi.org/10.1007/s12028-021-01429-4.
Kraig RP, Nicholson C. Extracellular ionic variations during spreading depression. Neuroscience. 1978;3(11):1045–59.
Dreier JP, Isele T, Reiffurth C, Offenhauser N, Kirov SA, Dahlem MA, Herreras O. Is spreading depolarization characterized by an abrupt, massive release of Gibbs free energy from the human brain cortex? Neuroscientist. 2013;19(1):25–42. https://doi.org/10.1177/1073858412453340.
Dreier JP, Reiffurth C. The stroke-migraine depolarization continuum. Neuron. 2015;86(4):902–22. https://doi.org/10.1016/j.neuron.2015.04.004.
Revankar GS, Winkler MKL, Major S, Schoknecht K, Heinemann U, Woitzik J, et al. Spreading depolarizations and seizures in clinical subdural electrocorticographic recordings. In: Claassen J, editor., et al., Varelas PN. Seizures in critical care. A guide to diagnosis and therapeutics. New York: Springer; 2017. p. 77–90.
Fabricius M, Fuhr S, Willumsen L, Dreier JP, Bhatia R, Boutelle MG, et al. Association of seizures with cortical spreading depression and peri-infarct depolarisations in the acutely injured human brain. Clin Neurophysiol. 2008;119(9):1973–84. https://doi.org/10.1016/j.clinph.2008.05.025. (S1388-2457(08)00554-3 [pii]).
Dreier JP, Major S, Pannek HW, Woitzik J, Scheel M, Wiesenthal D, et al. Spreading convulsions, spreading depolarization and epileptogenesis in human cerebral cortex. Brain. 2012;135(Pt 1):259–75. https://doi.org/10.1093/brain/awr303. (awr303 [pii]).
Nasretdinov A, Vinokurova D, Lemale CL, Burkhanova-Zakirova G, Chernova K, Makarova J, et al. Diversity of cortical activity changes beyond depression during spreading depolarizations. Nat Commun. 2023;14(1):7729. https://doi.org/10.1038/s41467-023-43509-3.
van Harreveld A, Stamm JS. Spreading cortical convulsions and depressions. J Neurophysiol. 1953;16(4):352–66.
Kaufmann D, Theriot JJ, Zyuzin J, Service CA, Chang JC, Tang YT, et al. Heterogeneous incidence and propagation of spreading depolarizations. J Cereb Blood Flow Metab. 2017;37(5):1748–62. https://doi.org/10.1177/0271678X16659496.
Milakara D, Grozea C, Dahlem M, Major S, Winkler MKL, Luckl J, et al. Simulation of spreading depolarization trajectories in cerebral cortex: correlation of velocity and susceptibility in patients with aneurysmal subarachnoid hemorrhage. NeuroImage Clin. 2017;16:524–38. https://doi.org/10.1016/j.nicl.2017.09.005.
Woitzik J, Hecht N, Pinczolits A, Sandow N, Major S, Winkler MK, et al. Propagation of cortical spreading depolarization in the human cortex after malignant stroke. Neurology. 2013;80(12):1095–102. https://doi.org/10.1212/WNL.0b013e3182886932.
Kang EJ, Prager O, Lublinsky S, Oliveira-Ferreira AI, Reiffurth C, Major S, et al. Stroke-prone salt-sensitive spontaneously hypertensive rats show higher susceptibility to spreading depolarization (SD) and altered hemodynamic responses to SD. J Cereb Blood Flow Metab. 2023;43:210–30. https://doi.org/10.1177/0271678X221135085.
Dreier JP, Lemale CL, Kola V, Friedman A, Schoknecht K. Spreading depolarization is not an epiphenomenon but the principal mechanism of the cytotoxic edema in various gray matter structures of the brain during stroke. Neuropharmacology. 2018;134(Pt B):189–207. https://doi.org/10.1016/j.neuropharm.2017.09.027.
Dietz RM, Weiss JH, Shuttleworth CW. Zn2+ influx is critical for some forms of spreading depression in brain slices. J Neurosci. 2008;28(32):8014–24. https://doi.org/10.1523/JNEUROSCI.0765-08.2008. (28/32/8014 [pii]).
Gerkau NJ, Rakers C, Petzold GC, Rose CR. Differential effects of energy deprivation on intracellular sodium homeostasis in neurons and astrocytes. J Neurosci Res. 2017;95(11):2275–85. https://doi.org/10.1002/jnr.23995.
Brini M, Cali T, Ottolini D, Carafoli E. Neuronal calcium signaling: function and dysfunction. Cell Mol Life Sci: CMLS. 2014;71(15):2787–814. https://doi.org/10.1007/s00018-013-1550-7.
Hernansanz-Agustin P, Choya-Foces C, Carregal-Romero S, Ramos E, Oliva T, Villa-Pina T, et al. Na(+) controls hypoxic signalling by the mitochondrial respiratory chain. Nature. 2020;586(7828):287–91. https://doi.org/10.1038/s41586-020-2551-y.
Geisberger S, Bartolomaeus H, Neubert P, Willebrand R, Zasada C, Bartolomaeus T, et al. Salt transiently inhibits mitochondrial energetics in mononuclear phagocytes. Circulation. 2021;144(2):144–58. https://doi.org/10.1161/CIRCULATIONAHA.120.052788.
Somjen GG. Irreversible hypoxic (ischemic) neuron injury. In: Somjen GG, editor. Ions in the brain. New York: Oxford University Press; 2004. p. 338–72.
Symon L, Branston NM, Strong AJ. Extracellular potassium activity, evoked potential and rCBF during experimental cerebral ischaemia in the baboon. Acta Neurol Scand Suppl. 1977;64:110–1.
Hossmann KA. Viability thresholds and the penumbra of focal ischemia. Ann Neurol. 1994;36(4):557–65. https://doi.org/10.1002/ana.410360404.
Bere Z, Obrenovitch TP, Kozak G, Bari F, Farkas E. Imaging reveals the focal area of spreading depolarizations and a variety of hemodynamic responses in a rat microembolic stroke model. J Cereb Blood Flow Metab. 2014;34(10):1695–705. https://doi.org/10.1038/jcbfm.2014.136.
Jarvis CR, Anderson TR, Andrew RD. Anoxic depolarization mediates acute damage independent of glutamate in neocortical brain slices. Cereb Cortex. 2001;11(3):249–59.
Dreier JP, Kleeberg J, Petzold G, Priller J, Windmuller O, Orzechowski HD, et al. Endothelin-1 potently induces Leao’s cortical spreading depression in vivo in the rat: a model for an endothelial trigger of migrainous aura? Brain. 2002;125(Pt 1):102–12.
Ayad M, Verity MA, Rubinstein EH. Lidocaine delays cortical ischemic depolarization: relationship to electrophysiologic recovery and neuropathology. J Neurosurg Anesthesiol. 1994;6(2):98–110.
Memezawa H, Smith ML, Siesjo BK. Penumbral tissues salvaged by reperfusion following middle cerebral artery occlusion in rats. Stroke. 1992;23(4):552–9.
Han S, Contreras MI, Bazrafkan A, Rafi M, Dara SM, Orujyan A, et al. Cortical anoxic spreading depolarization during cardiac arrest is associated with remote effects on peripheral blood pressure and postresuscitation neurological outcome. Neurocrit Care. 2022;37(Suppl 1):139–54. https://doi.org/10.1007/s12028-022-01530-2.
Shen Q, Ren H, Cheng H, Fisher M, Duong TQ. Functional, perfusion and diffusion MRI of acute focal ischemic brain injury. J Cereb Blood Flow Metab. 2005;25(10):1265–79. https://doi.org/10.1038/sj.jcbfm.9600132.
Pignataro G, Simon RP, Boison D. Transgenic overexpression of adenosine kinase aggravates cell death in ischemia. J Cereb Blood Flow Metab. 2007;27(1):1–5. https://doi.org/10.1038/sj.jcbfm.9600334.
Heiss WD, Rosner G. Functional recovery of cortical neurons as related to degree and duration of ischemia. Ann Neurol. 1983;14(3):294–301. https://doi.org/10.1002/ana.410140307.
Steen PA, Michenfelder JD, Milde JH. Incomplete versus complete cerebral ischemia: improved outcome with a minimal blood flow. Ann Neurol. 1979;6(5):389–98. https://doi.org/10.1002/ana.410060503.
Charriaut-Marlangue C, Margaill I, Represa A, Popovici T, Plotkine M, Ben-Ari Y. Apoptosis and necrosis after reversible focal ischemia: an in situ DNA fragmentation analysis. J Cereb Blood Flow Metab. 1996;16(2):186–94. https://doi.org/10.1097/00004647-199603000-00002.
Major S, Petzold GC, Reiffurth C, Windmuller O, Foddis M, Lindauer U, et al. A role of the sodium pump in spreading ischemia in rats. J Cereb Blood Flow Metab. 2017;37(5):1687–705. https://doi.org/10.1177/0271678X16639059.
Oliveira-Ferreira AI, Milakara D, Alam M, Jorks D, Major S, Hartings JA, et al. Experimental and preliminary clinical evidence of an ischemic zone with prolonged negative DC shifts surrounded by a normally perfused tissue belt with persistent electrocorticographic depression. J Cereb Blood Flow Metab. 2010;30(8):1504–19. https://doi.org/10.1038/jcbfm.2010.40.
Drenckhahn C, Winkler MK, Major S, Scheel M, Kang EJ, Pinczolits A, et al. Correlates of spreading depolarization in human scalp electroencephalography. Brain. 2012;135(Pt 3):853–68. https://doi.org/10.1093/brain/aws010.
Vinokurova D, Zakharov A, Chernova K, Burkhanova-Zakirova G, Horst V, Lemale CL, et al. Depth-profile of impairments in endothelin-1 - induced focal cortical ischemia. J Cereb Blood Flow Metab. 2022;42(10):1944–60. https://doi.org/10.1177/0271678X221107422.
Higuchi T, Takeda Y, Hashimoto M, Nagano O, Hirakawa M. Dynamic changes in cortical NADH fluorescence and direct current potential in rat focal ischemia: relationship between propagation of recurrent depolarization and growth of the ischemic core. J Cereb Blood Flow Metab. 2002;22(1):71–9. https://doi.org/10.1097/00004647-200201000-00009.
Koroleva VI, Bures J. The use of spreading depression waves for acute and long-term monitoring of the penumbra zone of focal ischemic damage in rats. Proc Natl Acad Sci U S A. 1996;93(8):3710–4.
Shuttleworth CW, Andrew RD, Akbari Y, Ayata C, Balu R, Brennan KC, et al. Which spreading depolarizations are deleterious to brain tissue? Neurocrit Care. 2019. https://doi.org/10.1007/s12028-019-00776-7.
Sugimoto K, Yang J, Fischer P, Takizawa T, Mulder IA, Qin T, et al. Optogenetic spreading depolarizations do not worsen acute ischemic stroke outcome. Stroke. 2023;54(4):1110–9. https://doi.org/10.1161/STROKEAHA.122.041351.
Busch E, Gyngell ML, Eis M, Hoehn-Berlage M, Hossmann KA. Potassium-induced cortical spreading depressions during focal cerebral ischemia in rats: contribution to lesion growth assessed by diffusion-weighted NMR and biochemical imaging. J Cereb Blood Flow Metab. 1996;16(6):1090–9. https://doi.org/10.1097/00004647-199611000-00002.
Takano K, Latour LL, Formato JE, Carano RA, Helmer KG, Hasegawa Y, et al. The role of spreading depression in focal ischemia evaluated by diffusion mapping. Ann Neurol. 1996;39(3):308–18. https://doi.org/10.1002/ana.410390307.
Dreier JP, Kleeberg J, Alam M, Major S, Kohl-Bareis M, Petzold GC, et al. Endothelin-1-induced spreading depression in rats is associated with a microarea of selective neuronal necrosis. Exp Biol Med (Maywood). 2007;232(2):204–13 (232/2/204 [pii]).
Dijkhuizen RM, Beekwilder JP, van der Worp HB, van der Sprenkel JWB, Tulleken KAF, Nicolay K. Correlation between tissue depolarizations and damage in focal ischemic rat brain. Brain Res. 1999;840(1–2):194–205 (S0006-8993(99)01769-2 [pii]).
Nedergaard M, Hansen AJ. Spreading depression is not associated with neuronal injury in the normal brain. Brain Res. 1988;449(1–2):395–8 (0006-8993(88)91062-1 [pii]).
Coburn C, Allman E, Mahanti P, Benedetto A, Cabreiro F, Pincus Z, et al. Anthranilate fluorescence marks a calcium-propagated necrotic wave that promotes organismal death in C. elegans. PLoS Biol. 2013;11(7):e1001613. https://doi.org/10.1371/journal.pbio.1001613.
Toyota M, Spencer D, Sawai-Toyota S, Jiaqi W, Zhang T, Koo AJ, et al. Glutamate triggers long-distance, calcium-based plant defense signaling. Science. 2018;361(6407):1112–5. https://doi.org/10.1126/science.aat7744.
Fordsmann JC, Ko RW, Choi HB, Thomsen K, Witgen BM, Mathiesen C, et al. Increased 20-HETE synthesis explains reduced cerebral blood flow but not impaired neurovascular coupling after cortical spreading depression in rat cerebral cortex. J Neurosci. 2013;33(6):2562–70. https://doi.org/10.1523/JNEUROSCI.2308-12.2013.
Lauritzen M. Pathophysiology of the migraine aura. The spreading depression theory. Brain. 1994;117(Pt 1):199–210.
Dreier JP, Korner K, Ebert N, Gorner A, Rubin I, Back T, et al. Nitric oxide scavenging by hemoglobin or nitric oxide synthase inhibition by N-nitro-L-arginine induces cortical spreading ischemia when K+ is increased in the subarachnoid space. J Cereb Blood Flow Metab. 1998;18(9):978–90. https://doi.org/10.1097/00004647-199809000-00007.
Dreier JP, Ebert N, Priller J, Megow D, Lindauer U, Klee R, et al. Products of hemolysis in the subarachnoid space inducing spreading ischemia in the cortex and focal necrosis in rats: a model for delayed ischemic neurological deficits after subarachnoid hemorrhage? J Neurosurg. 2000;93(4):658–66. https://doi.org/10.3171/jns.2000.93.4.0658.
Sugimoto K, Nomura S, Shirao S, Inoue T, Ishihara H, Kawano R, et al. Cilostazol decreases duration of spreading depolarization and spreading ischemia after aneurysmal subarachnoid hemorrhage. Ann Neurol. 2018;84(6):873–85. https://doi.org/10.1002/ana.25361.
Eriksen N, Rostrup E, Fabricius M, Scheel M, Major S, Winkler MKL, et al. Early focal brain injury after subarachnoid hemorrhage correlates with spreading depolarizations. Neurology. 2019;92(4):e326–41. https://doi.org/10.1212/WNL.0000000000006814.
Wolf S, Mielke D, Barner C, Malinova V, Kerz T, Wostrack M, et al. Effectiveness of lumbar cerebrospinal fluid drain among patients with aneurysmal subarachnoid hemorrhage: a randomized clinical trial. JAMA Neurol. 2023. https://doi.org/10.1001/jamaneurol.2023.1792.
Hugelshofer M, Buzzi RM, Schaer CA, Richter H, Akeret K, Anagnostakou V, et al. Haptoglobin administration into the subarachnoid space prevents hemoglobin-induced cerebral vasospasm. J Clin Invest. 2019;129(12):5219–35. https://doi.org/10.1172/JCI130630.
Dreier JP, Windmuller O, Petzold G, Lindauer U, Einhaupl KM, Dirnagl U. Ischemia triggered by red blood cell products in the subarachnoid space is inhibited by nimodipine administration or moderate volume expansion/hemodilution in rats. Neurosurgery. 2002;51(6):1457–65 (discussion 65-7).
Schneider UC, Xu R, Vajkoczy P. Inflammatory events following subarachnoid hemorrhage (SAH). Curr Neuropharmacol. 2018;16(9):1385–95. https://doi.org/10.2174/1570159X16666180412110919.
Gusdon AM, Savarraj J, Zhu L, Pandit PKT, Dore S, McBride DW, et al. Haptoglobin genotype affects inflammation after aneurysmal subarachnoid hemorrhage. Curr Neurovasc Res. 2020;17(5):652–9. https://doi.org/10.2174/1567202617666201214104623.
Woitzik J, Dreier JP, Hecht N, Fiss I, Sandow N, Major S, et al. Delayed cerebral ischemia and spreading depolarization in absence of angiographic vasospasm after subarachnoid hemorrhage. J Cereb Blood Flow Metab. 2012;32(2):203–12. https://doi.org/10.1038/jcbfm.2011.169. (jcbfm2011169 [pii]).
Minhas PS, Menon DK, Smielewski P, Czosnyka M, Kirkpatrick PJ, Clark JC, Pickard JD. Positron emission tomographic cerebral perfusion disturbances and transcranial Doppler findings among patients with neurological deterioration after subarachnoid hemorrhage. Neurosurgery. 2003;52(5):1017–22 (discussion 22-4).
Vergouwen MD, Algra A, Rinkel GJ. Endothelin receptor antagonists for aneurysmal subarachnoid hemorrhage: a systematic review and meta-analysis update. Stroke. 2012;43(10):2671–6. https://doi.org/10.1161/STROKEAHA.112.666693.
Etminan N, Vergouwen MD, Ilodigwe D, Macdonald RL. Effect of pharmaceutical treatment on vasospasm, delayed cerebral ischemia, and clinical outcome in patients with aneurysmal subarachnoid hemorrhage: a systematic review and meta-analysis. J Cereb Blood Flow Metab. 2011;31(6):1443–51. https://doi.org/10.1038/jcbfm.2011.7. (jcbfm20117 [pii]).
Vergouwen MD, Etminan N, Ilodigwe D, Macdonald RL. Lower incidence of cerebral infarction correlates with improved functional outcome after aneurysmal subarachnoid hemorrhage. J Cereb Blood Flow Metab. 2011;31(7):1545–53. https://doi.org/10.1038/jcbfm.2011.56. (jcbfm201156 [pii]).
Feuerstein D, Takagaki M, Gramer M, Manning A, Endepols H, Vollmar S, et al. Detecting tissue deterioration after brain injury: regional blood flow level versus capacity to raise blood flow. J Cereb Blood Flow Metab. 2014;34(7):1117–27. https://doi.org/10.1038/jcbfm.2014.53.
Sukhotinsky I, Dilekoz E, Moskowitz MA, Ayata C. Hypoxia and hypotension transform the blood flow response to cortical spreading depression from hyperemia into hypoperfusion in the rat. J Cereb Blood Flow Metab. 2008;28(7):1369–76. https://doi.org/10.1038/jcbfm.2008.35.
Hartings JA, Li C, Hinzman JM, Shuttleworth CW, Ernst GL, Dreier JP, et al. Direct current electrocorticography for clinical neuromonitoring of spreading depolarizations. J Cereb Blood Flow Metab. 2017;37(5):1857–70. https://doi.org/10.1177/0271678X16653135.
Sivakumar S, Tsetsou S, Patel AB, Stapleton CJ, Grannan BL, Schweitzer JS, et al. Cortical spreading depolarizations and clinically measured scalp EEG activity after aneurysmal subarachnoid hemorrhage and traumatic brain injury. Neurocrit Care. 2022;37(Suppl 1):49–59. https://doi.org/10.1007/s12028-021-01418-7.
Jeffcote T, Hinzman JM, Jewell SL, Learney RM, Pahl C, Tolias C, et al. Detection of spreading depolarization with intraparenchymal electrodes in the injured human brain. Neurocrit Care. 2014;20(1):21–31. https://doi.org/10.1007/s12028-013-9938-7.
Hartings JA, Wilson JA, Hinzman JM, Pollandt S, Dreier JP, DiNapoli V, et al. Spreading depression in continuous electroencephalography of brain trauma. Ann Neurol. 2014;76(5):681–94. https://doi.org/10.1002/ana.24256.
Hofmeijer J, van Kaam CR, van de Werff B, Vermeer SE, Tjepkema-Cloostermans MC, van Putten M. Detecting cortical spreading depolarization with full band scalp electroencephalography: an illusion? Front Neurol. 2018;9:17. https://doi.org/10.3389/fneur.2018.00017.
Hund SJ, Brown BR, Lemale CL, Menon PG, Easley KA, Dreier JP, Jones SC. Numerical simulation of concussive-generated cortical spreading depolarization to optimize DC-EEG electrode spacing for noninvasive visual detection. Neurocrit Care. 2022. https://doi.org/10.1007/s12028-021-01430-x.
Bastany ZJR, Askari S, Dumont GA, Kellinghaus C, Kazemi A, Gorji A. Association of cortical spreading depression and seizures in patients with medically intractable epilepsy. Clin Neurophysiol. 2020;131(12):2861–74. https://doi.org/10.1016/j.clinph.2020.09.016.
Major S, Gajovic-Eichelmann N, Woitzik J, Dreier JP. Oxygen-induced and pH-induced direct current artifacts on invasive platinum/iridium electrodes for electrocorticography. Neurocrit Care. 2021. https://doi.org/10.1007/s12028-021-01358-2.
Lee WS, Lee JK, Lee SA, Kang JK, Ko TS. Complications and results of subdural grid electrode implantation in epilepsy surgery. Surg Neurol. 2000;54(5):346–51 (S0090-3019(00)00324-4 [pii]).
Drenckhahn C, Windler C, Major S, Kang EJ, Scheel M, Vajkoczy P, et al. Complications in Aneurysmal subarachnoid hemorrhage patients with and without subdural electrode strip for electrocorticography. J Clin Neurophysiol. 2016;33(3):250–9. https://doi.org/10.1097/WNP.0000000000000274.
Schumm L, Lemale CL, Major S, Hecht N, Nieminen-Kelha M, Zdunczyk A, et al. Physiological variables in association with spreading depolarizations in the late phase of ischemic stroke. J Cereb Blood Flow Metab. 2022;42(1):121–35. https://doi.org/10.1177/0271678X211039628.
Helbok R, Schiefecker AJ, Friberg C, Beer R, Kofler M, Rhomberg P, et al. Spreading depolarizations in patients with spontaneous intracerebral hemorrhage: association with perihematomal edema progression. J Cereb Blood Flow Metab. 2017;37(5):1871–82. https://doi.org/10.1177/0271678X16651269.
Dohmen C, Sakowitz OW, Fabricius M, Bosche B, Reithmeier T, Ernestus RI, et al. Spreading depolarizations occur in human ischemic stroke with high incidence. Ann Neurol. 2008;63(6):720–8. https://doi.org/10.1002/ana.21390.
Sueiras M, Thonon V, Santamarina E, Sanchez-Guerrero A, Poca MA, Quintana M, et al. Cortical spreading depression phenomena are frequent in ischemic and traumatic penumbra: a prospective study in patients with traumatic brain injury and large hemispheric ischemic stroke. J Clin Neurophysiol. 2021;38(1):47–55. https://doi.org/10.1097/WNP.0000000000000648.
Dreier JP, Fabricius M, Ayata C, Sakowitz OW, Shuttleworth CW, Dohmen C, et al. Recording, analysis, and interpretation of spreading depolarizations in neurointensive care: Review and recommendations of the COSBID research group. J Cereb Blood Flow Metab. 2017;37(5):1595–625. https://doi.org/10.1177/0271678X16654496.
Liu JY, Thom M, Catarino CB, Martinian L, Figarella-Branger D, Bartolomei F, et al. Neuropathology of the blood-brain barrier and pharmaco-resistance in human epilepsy. Brain. 2012;135(Pt 10):3115–33. https://doi.org/10.1093/brain/aws147.
Mestre H, Du T, Sweeney AM, Liu G, Samson AJ, Peng W, et al. Cerebrospinal fluid influx drives acute ischemic tissue swelling. Science. 2020;367(6483). https://doi.org/10.1126/science.aax7171.
Hatashita S, Hoff JT, Salamat SM. Ischemic brain edema and the osmotic gradient between blood and brain. J Cereb Blood Flow Metab. 1988;8(4):552–9. https://doi.org/10.1038/jcbfm.1988.96.
Jha RM, Kochanek PM, Simard JM. Pathophysiology and treatment of cerebral edema in traumatic brain injury. Neuropharmacology. 2019;145(Pt B):230–46. https://doi.org/10.1016/j.neuropharm.2018.08.004.
Kuroiwa T, Ueki M, Ichiki H, Kobayashi M, Suemasu H, Taniguchi I, Okeda R. Time course of tissue elasticity and fluidity in vasogenic brain edema. Acta Neurochir Suppl. 1997;70:87–90. https://doi.org/10.1007/978-3-7091-6837-0_27.
Sadeghian H, Lacoste B, Qin T, Toussay X, Rosa R, Oka F, et al. Spreading depolarizations trigger caveolin-1-dependent endothelial transcytosis. Ann Neurol. 2018;84(3):409–23. https://doi.org/10.1002/ana.25298.
Dreier JP, Jurkat-Rott K, Petzold GC, Tomkins O, Klingebiel R, Kopp UA, et al. Opening of the blood-brain barrier preceding cortical edema in a severe attack of FHM type II. Neurology. 2005;64(12):2145–7. https://doi.org/10.1212/01.WNL.0000176298.63840.99.
Santos E, Olivares-Rivera A, Major S, Sanchez-Porras R, Uhlmann L, Kunzmann K, et al. Lasting s-ketamine block of spreading depolarizations in subarachnoid hemorrhage: a retrospective cohort study. Crit Care. 2019;23(1):427. https://doi.org/10.1186/s13054-019-2711-3.
MacLean MA, Muradov JH, Greene R, Van Hameren G, Clarke DB, Dreier JP, et al. Memantine inhibits cortical spreading depolarization and improves neurovascular function following repetitive traumatic brain injury. Sci Adv. 2023;9(50):eadj2417. https://doi.org/10.1126/sciadv.adj2417.
Carlson AP, Abbas M, Alunday RL, Qeadan F, Shuttleworth CW. Spreading depolarization in acute brain injury inhibited by ketamine: a prospective, randomized, multiple crossover trial. J Neurosurg. 2018;1–7. https://doi.org/10.3171/2017.12.JNS171665.
Hartings JA, Dreier JP, Ngwenya LB, Balu R, Carlson AP, Foreman B. Improving neurotrauma by depolarization inhibition with combination therapy: a phase 2 randomized feasibility trial. Neurosurgery. 2023. https://doi.org/10.1227/neu.0000000000002509.
Sakowitz OW, Kiening KL, Krajewski KL, Sarrafzadeh AS, Fabricius M, Strong AJ, et al. Preliminary evidence that ketamine inhibits spreading depolarizations in acute human brain injury. Stroke. 2009;40(8):e519–22. https://doi.org/10.1161/STROKEAHA.109.549303.
Hertle DN, Dreier JP, Woitzik J, Hartings JA, Bullock R, Okonkwo DO, et al. Effect of analgesics and sedatives on the occurrence of spreading depolarizations accompanying acute brain injury. Brain. 2012;135(Pt 8):2390–8. https://doi.org/10.1093/brain/aws152.
Schoknecht K, Kikhia M, Lemale CL, Liotta A, Lublinsky S, Mueller S, et al. The role of spreading depolarizations and electrographic seizures in early injury progression of the rat photothrombosis stroke model. J Cereb Blood Flow Metab. 2021;41(2):413–30. https://doi.org/10.1177/0271678X20915801.
Westermaier T, Pham M, Stetter C, Willner N, Solymosi L, Ernestus RI, et al. Value of transcranial Doppler, perfusion-CT and neurological evaluation to forecast secondary ischemia after aneurysmal SAH. Neurocrit Care. 2014;20(3):406–12. https://doi.org/10.1007/s12028-013-9896-0.
Vatter H, Guresir E, Konig R, Durner G, Kalff R, Schuss P, et al. Invasive diagnostic and therapeutic management of cerebral vasospasm after aneurysmal subarachnoid hemorrhage (IMCVS)-a phase 2 randomized controlled trial. J Clin Med. 2022;11(20). https://doi.org/10.3390/jcm11206197.
Dreier JP, Victorov IV, Petzold GC, Major S, Windmuller O, Fernandez-Klett F, et al. Electrochemical failure of the brain cortex is more deleterious when it is accompanied by low perfusion. Stroke. 2013;44(2):490–6. https://doi.org/10.1161/STROKEAHA.112.660589.
Ng ZX, Yang WR, Seet E, Koh KM, Teo KJ, Low SW, et al. Cerebellar strokes: a clinical outcome review of 79 cases. Singapore Med J. 2015;56(3):145–9. https://doi.org/10.11622/smedj.2014195.
Aboghazleh R, Parker E, Yang LT, Kaufer D, Dreier JP, Friedman A, van Hameren G. Brainstem and cortical spreading depolarization in a closed head injury rat model. Int J Mol Sci. 2021;22(21). https://doi.org/10.3390/ijms222111642.
Hutchinson PJ, Kolias AG, Menon DK. Craniectomy for traumatic intracranial hypertension. N Engl J Med. 2016;375(24):2403–4. https://doi.org/10.1056/NEJMc1613479.
Funding
Open Access funding enabled and organized by Projekt DEAL. Dr. Dreier was supported by the following grants: Era-Net Neuron EBio2 with funds from BMBF 01EW2004 and DFG DR 323/10–2. Dr. Hecht is BIH clinical fellow, funded by Stiftung Charité.
Author information
Authors and Affiliations
Contributions
JPD: drafted the manuscript and approved the final version of the manuscript.
CLL: created Figs. 2–7, contributed to the manuscript, and approved the final version of the manuscript.
VH: created Fig. 1, contributed to the manuscript, and approved the final version of the manuscript.
SM, VK, KS, MS, JAH, PV, SW, JW, and NH contributed to the manuscript and approved the final version of the manuscript.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Ethics Approval and Consent to Participate
All procedures performed involving patients were in accordance with the ethical standards of the institutional research committees and with the 1964 Helsinki Declaration and its later amendments. Either informed consent or surrogate informed consent was obtained for all patients.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Dreier, J.P., Lemale, C.L., Horst, V. et al. Similarities in the Electrographic Patterns of Delayed Cerebral Infarction and Brain Death After Aneurysmal and Traumatic Subarachnoid Hemorrhage. Transl. Stroke Res. (2024). https://doi.org/10.1007/s12975-024-01237-w
Received:
Revised:
Accepted:
Published:
DOI: https://doi.org/10.1007/s12975-024-01237-w